A RANDOMIZED CONTROL TRIAL ON EFFICACY OF DIPEROXOCHLORIC ACID IN MANAGEMENT OF NECROTIC WOUND COMPARED TO CONVENTIONAL DRESSINGS USINGBATES JENSEN WOUND ASSESSMENT TOOL - NIL

Start Date05 Dec 2024

Sponsor / Collaborator-

CTRI/2024/05/068094

/ RecruitingPhase 3

A multicenter, randomized, double-blind, active-control phase III clinical trial of WOXheal® [Diperoxochloric acid] topical solution in the treatment of pressure ulcers – in comparison with the active-control 0.9% sodium chloride topical solution in addition to standard of care - NIL

Start Date07 Jun 2024

Sponsor / Collaborator

Centaur Pharmaceuticals Pvt Ltd.

CTRI/2023/06/054253

/ RecruitingPhase 3

A multicenter, randomized, double-blind, active-control phase III clinical trial of WOXheal® [Diperoxochloric acid] topical solution in the treatment of chronic venous leg ulcer – in comparison with the active-control 0.9% sodium chloride topical solution in addition to standard of care.

Start Date03 Jul 2023

Sponsor / Collaborator

Centaur Pharmaceuticals Pvt Ltd.

100 Clinical Results associated with Diperoxochloric acid

100 Translational Medicine associated with Diperoxochloric acid

100 Patents (Medical) associated with Diperoxochloric acid

Literatures (Medical) associated with Diperoxochloric acid

24 Aug 2025·Cureus Journal of Medical Science

Use of Diperoxochloric Acid as a Novel Therapy for the Treatment of Infected Traumatic Foot Ulcers: A Case Series

Article

Author: Ahmad, Samir ; Shahnaz Masthan, Haritha ; K, Bharathi Raja ; R G, Santhaseelan ; Guru Prasad, N

Infected traumatic foot ulcers present a significant therapeutic challenge, particularly in patients with delayed presentation, suboptimal hygiene, or comorbidities like diabetes and peripheral vascular disease. Conventional management includes wound debridement, systemic antibiotics, and advanced dressings, often with variable success. Diperoxochloric acid (DPA), a potent oxidizing agent with broad-spectrum antimicrobial properties, has recently gained attention for its potential in promoting wound healing while simultaneously reducing the microbial load. In this case series, we present four patients with moderate to severe infected foot ulcers following trauma, all of whom showed minimal improvement after at least 14 days of standard wound care and systemic antibiotic therapy. Upon introduction of topical DPA as an adjunctive treatment along with serial wound debridement, all cases demonstrated significant clinical improvement, with a rapid reduction in wound size (average decrease of 60% within three weeks), resolution of infection, and progressive granulation leading to complete healing in an average of 6.5 weeks. Compared to traditional antiseptics, DPA offers several advantages, including reduced cytotoxicity, sustained antimicrobial activity, and enhanced wound bed preparation, making it a compelling adjunct in chronic and infected wound care. This series highlights the potential of DPA as a cost-effective, efficient, and well-tolerated adjunct in the multidisciplinary management of infected traumatic foot ulcers. Future prospective studies with larger cohorts are warranted to further elucidate optimal protocols, long-term outcomes, and cost-effectiveness.

01 Dec 2024·The international journal of lower extremity woundsQ4 · MEDICINE

Efficacy and Safety of Topical Solution of Diperoxochloric Acid for Neuropathic Diabetic Foot Ulcer: Results from a Phase 3, Multicentre, Randomized, Active-controlled, Parallel-group Study

Q4 · MEDICINE

Article

Author: Jagannath ; Damle, Gauri ; Munshi, Renuka ; Phal, Smita ; Zarapkar, Mukund ; Bal, Arun ; Chowdhury, Subhankar ; Mahey, Rajeshkumar ; Deshpande, Neeta ; Bhaskar, M.M. ; Singh, Sapam Opendro ; Mohapatra, Kailash Chandra ; Jain, Sudhir Kumar ; Damir, Ashok ; Rao, Shilpa

Diabetic foot ulcer (DFU), if untreated, accounts for lower-limb amputations affecting patients’ quality-of-life. Diperoxochloric acid (DPOCL) is known to heal DFU by its antibacterial and fibroblast stimulating activity. This was a phase 3, multicentre, randomized, double-blind, active-controlled, parallel-group study conducted to evaluate the efficacy and safety of topic solution of DPOCL compared with isotonic sodium chloride solution (ISCL). Adult patients with type 1 or 2 diabetes with random blood glucose levels of <250 mg/dL, with ≤ than three full-thickness foot ulcers were enrolled. Primary efficacy endpoint was complete wound closure and secondary was wound surface area. Adverse events were analyzed as safety endpoint. Of 311 enrolled patients, 289 were randomized 1:1 to DPOCL (139) and ISCL (150) treatment (10-weeks [8-Visits]). Percentage of patients with complete wound closure at visit-8, were significantly higher ( P = .0156) in DPOCL arm (76% [105/139]) compared to ISCL (62% [93/150]) arm. At end-of-study, mean wound surface area in DPOCL arm (0.639 cm2) was significantly lower ( P = .0209) compared to ISCL (0.818 cm2) arm. One death was reported in control arm which was not considered as treatment-related. No important safety finding were observed. Results indicate that, DPOCL can be considered as effective and safe treatment option for DFU compared to ISCL, although future confirmatory studies are warranted.

International journal of oncologyQ2 · MEDICINE

Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 and granulocyte-macrophage colony stimulating factor (GM-CSF): II. Adverse effects of GM-CSF

Q2 · MEDICINE

Article

Author: Pavel Dundr ; Vladimír Vonka ; Martina Petráčková ; Libor Staněk ; Václav Mandys

Granulocyte-macrophage colony stimulating factor (GM-CSF) is considered to be the most effective immunostimulating factor for the construction of gene-engineered anti-cancer vaccines. In some tumour cells, this type of genetic modification has resulted in the loss of the oncogenic potential. This was not the case with bcr-abl-transformed mouse 12B1 cells. A cell line, designated 12B1/GM-CSF/cl-5 producing more than 100 ng/106 cells/24 h, displayed higher pathogenicity than the parental, non-transduced cells. Although the tumours induced by the parental 12B1 cells and 12B1/GM-CSF/cl-5 cells appeared nearly at the same time and then grew at an approximately equal rate, the latter mice were in a much poorer clinical condition. In these animals the growth of the tumours was associated with gradually increasing blood levels of GM-CSF. In both groups of animals splenomegaly was observed; it was much more pronounced in the case of 12B1/GM-CSF/cl-5-inoculated animals. While in the case of animals inoculated with the parental cells the splenomegaly was probably mainly due to infiltration with tumour cells, in the animals inoculated with the GM-CSF-secreting cells splenomegaly and derangement of parenchymal organs, such as lungs, liver and kidneys, were more complex, including congestion and infiltration with hemopoietic cells, predominantly immature cells of myeloid lineage. The most conspicuous of these changes was the hyperaemia of the lungs. No such alterations were seen in animals inoculated with the parental cells. On the other hand, the contents of T regulatory cells were comparable in both groups and they increased in parallel at the end of the observation period. When GM-CSF neutralizing antibody was administered to animals inoculated with the 12B1/GM-CSF/cl-5 cells, the pathological changes observed within the organs were suppressed, this proving that the overproduced GM-CSF and not any other substance, played the key role in their induction.

News (Medical) associated with Diperoxochloric acid

27 Oct 2018

·www.bioportfolio.com

CytoTools AG T5O Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

Summary CytoTools AG CytoTools, formerly CytoTools GmbH is a biotechnology company that develops new therapies and medical products for wound healing, urinary tract infections and cardiovascular diseases. The company's product includes DermaPro for diabetic foot ulcer and venous leg ulcer; DermaPro Pep04 for burns; CardioClean for restenosis, diabetes, and carotisstenosis; LMW 0x for arteriosclerosis; HMW 02Ac for diagnostic; and Utisept for urinary tract infections. Its DermaPro product is derived from dichloric acid and is applied to poorly healing and chronic wounds by a moist wound dressing. CytoTools is headquartered in Darmstadt, Germany. CytoTools AG T5O Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Diperoxochloric acid

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic Foot	India	Centaur Pharmaceuticals Pvt Ltd.	15 Apr 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic foot ulcer	Phase 2	Estonia	Dermatools Biotech GmbH	06 Aug 2018
Burns	Preclinical	Germany	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis